Agios Pharmaceuticals ended development of its next-generation sickle cell drug tebapivat after Phase 2 results failed to demonstrate a differentiated profile, the company said. Agios’ decision adds to a series of sickle cell clinical setbacks for the category of pyruvate kinase activator therapies. Tebapivat, a second-generation oral activator, did not establish the level of differentiation required to continue, Agios said, and the company will halt the indication even as it advances other efforts. The failure also shifts attention to competing enzyme activators, particularly Novo Nordisk’s mitapivat (Pyrukynd), which remains the reference standard in the class, while investors increasingly look for evidence of clearer differentiation and registrational paths. The update reflects how hard it has been to maintain clinical momentum in sickle cell disease, where regulators and payers can be unforgiving on incremental efficacy and safety.